Saturday, May 13, 2023 10:00 AM – 10:45 AM ET Exhibit Hall D, Room 1
Exhibitor Workshop: Sony Biotechnology, Inc.
TAC-T Cells Elicit Durable Anti-Tumor Responses in Preclinical Models of Solid Tumors
- Heather L. MacGregor, Ph.D., Senior Scientist, Triumvira Immunologics Inc.
The T cell antigen coupler (TAC) is a novel chimeric receptor that redirects TAC-engineered T cells against tumor antigens and activates T cells via the endogenous T cell receptor complex. TAC01-HER2, a first-in-class TAC-T product targeting HER2 (ERBB2), has entered a phase I/II clinical trial. We characterized TAC-T cells during anti-tumor responses. Kinetics of proliferation, TCR signaling, activation, and memory generation by tumor-activated TAC-T cells were assessed by Sony® ID 7000 spectral flow cytometer and by scRNA-seq. The cytotoxic robustness was assessed through multiple rounds of tumor cell exposure in vitro and immunologic durability was tested in a xenograft tumor rechallenge study. We show that TAC-T product mounts a durable anti-tumor response, comprising functionally active T cells with robust self-renewal capacity that do not become terminally exhausted.